Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
8.13
+0.24 (3.04%)
Yopilishda: May 12, 2026, 4:00 PM EDT
7.86
-0.27 (-3.32%)
Bozor oldidan: May 13, 2026, 8:23 AM EDT
BridgeBio Oncology Therapeutics, Inc., klinik bosqichdagi biotexnologiya kompaniyasi, Qo'shma Shtatlarda renin-angiotensin tizimi va fosfoinozitid-3-kinaza xavfli o'smalarini davolash uchun kichik molekulali terapevtik vositalarni ishlab chiqish bilan shug'ullanadi. Kompaniya KRASG12C mutatsiyali mayda hujayrali o'pka saratoni bilan og'rigan bemorlarni davolash uchun I bosqich klinik sinovlarida bo'lgan og'iz orqali qabul qilinadigan kichik molekulali to'g'ridan-to'g'ri ingibitor BBO-8520ni ishlab chiqadi; va KRAS G12D va KRAS G12V hujayrali ksenograft modellariga ega bemorlarni davolash uchun I bosqich klinik sinovlarida bo'lgan og'iz orqali qabul qilinadigan kichik molekulali pan-KRAS ingibitor BBO-11818ni ishlab chiqadi. U, shuningdek, HER2-musbat ko'krak bezi saratoni, HR-musbat/HER2-manfiy ko'krak bezi saratoni, KRAS mutatsiyali kolorektal saraton va KRAS mutatsiyali mayda hujayrali o'pka saratoni bilan og'rigan bemorlarni davolash uchun I bosqich klinik sinovlarida bo'lgan og'iz orqali qabul qilinadigan kichik molekulali BBO-10203ni ishlab chiqishda ishtirok etadi; va o'smalari bo'lgan bemorlar uchun aniq onkologik vositalarni ishlab chiqadi. Kompaniya 2016 yilda tashkil etilgan bo'lib, shtab-kvartirasi Janubiy San-Frantsisko, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Frank P. McCormick Ph.D. | Co-Founder, Non-Executive Director & Chair of the Advisory Board |
| Dr. Neil Kumar Ph.D. | Executive Chairman |
| Dr. Pedro J. Beltran M.D., Ph.D. | Chief Executive Officer and Director |
| Dr. Yong Ben M.B.A., M.D. | Chief Medical & Development Officer |
| Mr. Aaron Chan J.D. | Vice President of Legal |
| Mr. Bin Wang Ph.D. | Senior Vice President of Drug Discovery |
| Mr. Daniel Watson Ph.D. | Senior Vice President of Chemistry, Manufacturing & Controls |
| Mr. Idan Elmelech M.A., M.B.A. | Chief Operating Officer |
| Mr. Marc Cobo | VP of Finance & Controller |
| Mr. Rui Xu Ph.D. | Senior Vice President of Drug Discovery |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | POS AM | d480864dposam.htm |
| 2026-04-28 | DEFA14A | d95309ddefa14a.htm |
| 2026-04-28 | ARS | d134712dars.pdf |
| 2026-04-23 | 8-K | d253464d8k.htm |
| 2026-03-05 | 10-K | bbot-20251231.htm |
| 2026-01-02 | S-8 | d11495ds8.htm |
| 2025-11-12 | 10-Q | bbot-20250930.htm |
| 2025-10-10 | S-8 | d51761ds8.htm |
| 2025-09-08 | CORRESP | filename1.htm |
| 2025-08-29 | S-1 | d67813ds1.htm |